Puma Biotechnology Inc PBYI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
74/100
Moderate

Ranked against 712 peers in Biotechnology

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, … Full PBYI analysis →

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.99), demonstrating pricing resilience across cycles.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.97), suggesting sticky customer base.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.22), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
77
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where PBYI ranks in Biotechnology

Puma Biotechnology Inc ranks #35 of 713 scored companies in Biotechnology by moat score — the top 5%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
31 Genmab A/S GMAB 75/100 Moderate
32 Pharming Group N.V. PHAR 74/100 Moderate
33 Alnylam Pharmaceuticals, Inc. ALNY 74/100 Moderate
34 BioCryst Pharmaceuticals, Inc. BCRX 74/100 Moderate
35 Puma Biotechnology Inc PBYI 74/100 Moderate
36 XOMA Royalty Corporation XOMA 73/100 Moderate
37 XOMA Royalty Corporation - Depo XOMAO 73/100 Moderate
38 XOMA Royalty Corporation - 8.62 XOMAP 73/100 Moderate
39 Vaxart, Inc. - Common Stock VXRT 73/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How PBYI scores on the Corporate Default defenses

Pricing Power

Score 77 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 90 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 93 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 68 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 57 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 59 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding PBYI's moat

What is Puma Biotechnology Inc's moat score?

Puma Biotechnology Inc (PBYI) scores 74 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #35 of 713 scored companies in Biotechnology, the top 5%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (93/100) and its weakest is Resilience (57/100).

How does Puma Biotechnology Inc compare with other Biotechnology companies?

Puma Biotechnology Inc ranks #35 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are BioCryst Pharmaceuticals, Inc. (BCRX) at 74 just above it and XOMA Royalty Corporation (XOMA) at 73 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Puma Biotechnology Inc scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Puma Biotechnology Inc?

The Corporate Default template measures 6 defenses, and PBYI scores: Pricing Power (77), Cost Advantage (90), Customer Stickiness (93), Capital Efficiency (68), Resilience (57), Scale & Market Position (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000